Drug Trial Radar · NCT04746924
A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer
Last checked: Nov 19, 2026Latest source record: May 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
669
Actual
Start
May 24, 2021
Primary completion
May 30, 2025
Study completion Mar 18, 2026
Sponsor
- Lead sponsor
- BeiGeneBeOne Medicines (BeiGene) (ONC)
- Sponsor type
- Industry
- First posted
- Feb 10, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of ociperlimab + tislelizumab compared with that of pembrolizumab in adults with high levels of programmed cell death ligand-1 (PD-L1), locally advanced/recurrent or untreated metastatic non-small cell lung cancer (NSCLC).
Conditions
- Non-small Cell Lung Cancer
- NSCLC
Interventions
TislelizumabDrug
Tislelizumab is a monoclonal antibody formulated for intravenous injection.
OciperlimabDrug
Ociperlimab is a monoclonal antibody formulated for intravenous injection.
PembrolizumabDrug
Pembrolizumab is a monoclonal antibody formulated for intravenous injection.
PlaceboDrug
Placebo infusions will consist of a sterile, normal saline solution.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival (OS) in Arms A and BTime frame: From randomization until the end of the study. Maximum time on study was 45.0 months
- Safety Run-In Substudy: Number of Participants Experiencing Adverse Events (AEs)Time frame: From first dose of study drug to 30 days after last dose. Maximum treatment duration was 12.45 months.
- Safety Run-In Substudy: Serum Concentration of OciperlimabTime frame: Cycle 1 Day 1 (C1D1) Postdose (30 minutes after end of infusion), 24 and 72 Hours Postdose; C1D8; C1D15; C2D1 Predose and Postdose; C5D1 Predose; C5D1 Postdose; C5D8; C5D15; C6D1 Predose and Postdose; C9D1 Predose; C13D1 Predose; End of Treatment.
Locations
218 sites in 19 countries. Site status is shown where the registry gives one.
Providence Medical Foundation St Jude Heritage Healthcare
Fullerton, California
Valkyrie Clinical Trials
Los Angeles, California
Ocala Oncology Center Pl Dba Florida Cancer Affiliates Ocala
Ocala, Florida
Advent Health Cancer Institute
Orlando, Florida
Goshen Center For Cancer Care
Goshen, Indiana
Baptist Health Lexington
Lexington, Kentucky
University Medical Center New Orleans West Jefferson Medical Center
New Orleans, Louisiana
Metro Minnesota Community Oncology Research Consortium (Mmcorc)
Saint Paul, Minnesota
West Penn Hospital
Pittsburgh, Pennsylvania
Centro Medical Austral
Buenos Aires, Argentina
Centro Para La Atencion Del Paciente Oncologico (Caipo)
San Miguel de Tucumán, Argentina
Concord Repatriation General Hospital
Concord, New South Wales, Australia
Northern Cancer Institute
St Leonards, New South Wales, Australia
Calvary Mater Newcastle
Waratah, New South Wales, Australia
Pindara Private Hospital
Benowa, Queensland, Australia
The Prince Charles Hospital
Chermside, Queensland, Australia
Mater Cancer Care Centre
South Brisbane, Queensland, Australia
John Flynn Private Hospital
Tugun, Queensland, Australia
Lyell McEwin Hospital
Elizabeth Vale, South Australia, Australia
Ballarat Health Services
Ballarat, Victoria, Australia
Monash Health
Clayton, Victoria, Australia
Western Health Sunshine Hospital
St Albans, Victoria, Australia
St John of God, Murdoch
Murdoch, Western Australia, Australia
Instituto Dor de Pesquisa E Ensino Distrito Federal
Brasília, Brazil
Hospital Evangelico de Cachoeiro de Itapemirim
Cachoeiro de Itapemirim, Brazil
Centro de Pesquisas Oncologicas Cepon
Florianópolis, Brazil
Cancer Institute of Ceara
Fortaleza, Brazil
Cepho Centro de Estudos E Pesquisas de Hematologia E Oncologia
Santo André, Brazil
Fundacao Faculdade Regional de Medicina de Sao Jose Do Rio Preto
São José do Rio Preto, Brazil
Anhui Provincial Hospital
Hefei, Anhui, China
The Second Hospital of Anhui Medical University
Hefei, Anhui, China
Beijing Chao Yang Hospital
Beijing, Beijing Municipality, China
Beijing Cancer Hospital
Beijing, Beijing Municipality, China
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China
Beijing Chest Hospital, Capital Medical University
Beijing, Beijing Municipality, China
Chongqing Cancer Hospital
Chongqing, Chongqing Municipality, China
The First Affiliated Hospital of Army Military Medical University
Chongqing, Chongqing Municipality, China
Daping Hospital, Third Military Medical University
Chongqing, Chongqing Municipality, China
Chongqing University Three Gorges Central Hospital
Chongqing, Chongqing Municipality, China
Fujian Medical University Union Hospital
Fuzhou, Fujian, China
Showing 40 of 218 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.